The announcement comes on the heels of a new round of financing that will help double Concure's field sales organization and train new clinicians across the United States in making Breast Microseed Treatment® available for women seeking breast cancer treatment. Those who have contributed to this round of funding include notable Seattle-area business and community leaders such as Jeff Wright, Chris Ackerley and Craig Tall.
Breast Microseed Treatment® is a safe, effective and convenient solution that goes beyond traditional radiation for early-stage breast cancer patients. This technique, also known as low-dose-rate brachytherapy, is based on a similar method that has already been proven to successfully treat prostate cancer. What distinguishes this treatment from conventional radiation therapy is that it allows post-lumpectomy patients the chance to have a one-time, one-hour procedure, as opposed to more burdensome conventional radiation treatments that may last from three to six weeks and require daily visits to a radiation facility.
About Concure Oncology
Concure Oncology was founded with the mission of easing the burden for women facing early-stage breast cancer by providing a treatment option that is safe, effective, and convenient. Led by a nationally recognized team of leaders from the medical industry, the Seattle area company is working with medical centers across the U.S. to bring Breast Microseed Treatment® to patients everywhere.
SOURCE Concure Oncology
Back to HCB News
